RemeGen Co., Ltd.

Languages

中文简体中文繁體 English

Telitacicept completed domestic phase II clinical study on IgA Nephropathy

2021-08-10

Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin

2021-08-09

First clinical trial permit in Australia of Remegen! RC118, an ADC drug targeting the Claudin18.2

2021-07-30

15
2021.07

Disitamab Vedotin has been granted breakthrough designations in the United States and China, new drug application (NDA) of urothelial carcinoma was accepted
30
2021.06

The first time in China! Two indications of Disitamab Vedotin have been granted breakthrough designations in the United States and China for three times
10
2021.06

Disitamab Vedotin has become the first ADC drug created and developed by a China biopharma to receive marketing approval!
21
2020.09

RemeGen Announces US FDA Has Granted Breakthrough Therapy Designation for Disitamab Vedotin (RC48) in Urothelial Cancer

1 / 1

RC48-ADC appeared on ASCO 2021 meeting again and brought exciting clinical data

2021-06-05

RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO

2020-06-17

荣昌生物房健民：做特立独行的ADC，找准适应症不扎堆

2020-04-04

1 / 1

58 Beijing Middle Road, Yantai Shandong, China.
（+86）0535-3573672
ppb@remegen.cn

Company Wechat

Terms of Use Privacy Policy Media Resources

© All Right Reserved . ICP：鲁ICP备11031710号-1